A Three-Year Study of Brain Atrophy after Autologous Hematopoietic Stem Cell Transplantation in Rapidly Evolving Secondary Progressive Multiple Sclerosis

Università degli Studi di Genova, Genova, Liguria, Italy
American Journal of Neuroradiology (Impact Factor: 3.59). 11/2007; 28(9):1659-61. DOI: 10.3174/ajnr.A0644
Source: PubMed


In multiple sclerosis (MS), autologous hematopoietic stem cell transplantation (AHSCT) induces a profound suppression of clinical activity and MR imaging-detectable inflammation, but it may be associated with a rapid brain volume loss in the months subsequent to treatment. The aim of this study was to assess how AHSCT affects medium-term evolution of brain atrophy in MS.
MR imaging scans of the brain from 14 patients with rapidly evolving secondary-progressive MS obtained 3 months before and every year after AHSCT for 3 years were analyzed. Baseline normalized brain volumes and longitudinal percentage of brain volume changes (PBVCs) were assessed using the Structural Image Evaluation of Normalized Atrophy software.
The median decrease of brain volume was 1.92% over the first year after AHSCT and then declined to 1.35% at the second year and to 0.69% at the third year. The number of enhancing lesions seen on the pretreatment scans was significantly correlated with the PBVCs between baseline and month 12 (r = -0.62; P = .02); no correlation was found with the PBVCs measured over the second and third years.
After AHSCT, the rate of brain tissue loss in patients with MS declines dramatically after the first 2 years. The initial rapid development of brain atrophy may be a late consequence of the pretransplant disease activity and/or a transient result of the intense immunoablative conditioning procedure.

Download full-text


Available from: Peter A W te Boekhorst, Oct 06, 2015
15 Reads
  • Source
    • "This rate remains essentially constant and high throughout the course of MS, from clinically isolated syndrome (CIS) to PP-MS [3] [4]. Interestingly, even in the RR-MS phase treated by the most active treatments for preventing relapses, i.e. alemtuzumab or autologous stem cell transplantation, the brain atrophy rate decreases but always fails to normalize and remains high [5] [6] [7] [8]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Multiple sclerosis impairment is mainly driven by the progressive phase, whose pathology remains elusive. No drug has yet been able to halt this phase so therapeutic management remains challenging. It was recently demonstrated that late disability correlates with the spreading of cortical subpial lesions, and tertiary lymphoid organs (TLO) were identified in close apposition with these lesions. TLO are of crucial importance since they are able to mount a complete local immune response, as observed in the intrathecal compartment from the moment MS is diagnosed (i.e. oligoclonal bands). This article examines the consequences of this intrathecal response: giving a worst clinical prognostic value and bearing arguments for possible direct brain toxicity, intrathecal secretion should be targeted by drugs abating both B-lymphocytes and plasma cells. Another consequence is that intrathecal secretion has value as a surrogate marker of the persistence of an ongoing intrathecal immune reaction after treatment. Although it is still unsure which mechanism or byproduct secreted by TLO triggers cortical lesions, we propose to target TLO components as a new therapeutic avenue in progressive MS.
    Medical Hypotheses 01/2013; 82(3). DOI:10.1016/j.mehy.2013.12.015 · 1.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Metabonomics based on pattern recognition methods was combined with 1H in vivo MRS in order to investigate the metabolic differences in normal-appearing white matter of multiple sclerosis patients. The studied group consisted of 21 patients (12 – CIS, 7 – RR, 3 – PP, 2 – SP), the spectra were acquired using the whole body 2T MRI/MRS system and analyzed with Partial Least Squares – Discriminant Analysis preceded with Orthogonal Signal Correction spectral filtering. The CIS class showed the highest NAA concentrations in comparison to clinically confirmed MS, and lower NAA as well as increased mI in CIS may suggest development of MS. Strongly elevated Lip was characteristic for RR, while increased Lac and probably mI as well as Glx distinguished SPMS. Surprisingly the PP class showed increased Ace and/or GABA. Pattern recognition methods were effectively combined with 1H in vivo MRS and revealed metabolic discriminative features between multiple sclerosis subtypes.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Intense immunosuppression followed by autologous haematopoietic-stem-cell transplantation (HSCT) is being assessed as a potential treatment for patients with severe multiple sclerosis (MS). The treatment was developed from research that showed autologous HSCT was as effective as allogeneic HSCT in the treatment of experimental autoimmune encephalomyelitis. The treatment is thought to eradicate the defective immune system, and the infused haematopoietic stem cells reconstitute an immune system that is more tolerant to the nervous system. About 250 patients with MS have been treated with autologous HSCT as part of phase I and phase II open trials. Autologous HSCT seems feasible in MS and assessment with clinical and MRI measures suggests it induces a profound and long-lasting suppression of inflammation. The course of MS seems to be stabilised after autologous HSCT, especially in ambulatory patients with evidence of active disease. Autologous HSCT deserves further study in randomised controlled trials.
    The Lancet Neurology 02/2005; 4(1):54-63. DOI:10.1016/S1474-4422(04)00966-4 · 21.90 Impact Factor
Show more